1)三村 治:甲状腺眼症.日眼会誌 113:1015-1030,2009
2)井上洋一:甲状腺眼症.眼科診療プラクティス90(眼窩疾患の診療):51-55,2003
3)Kuriyan AE, Phipps RP, Feldon SE:The eye and thyroid disease. Curr Opin Ophthalmol 19:499-506, 2008
4)Kanski JJ:Clinical Ophthalmology. Third ed. 32-38, Butterworth-Heinemann Oxford, 1994
5)安積 淳:Basedow病眼症でなぜ眼瞼に異常が起こるのか?.根木昭・田野保雄・大橋裕一・他(編):眼のサイエンス.眼疾患の謎.22-23,文光堂,東京,2010
6)Mourits MP, Koornneef L, Wiersinga WM et al:Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy:a novel approach. Br J Ophthalmol 73:639-644, 1989
7)Mourits MP, Prummel MF, Wiersinga WM et al:Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 47:9-14, 1997
8)Chee E, Chee SP:Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease:a case saries. Eye 22:311-315, 2008
9)Ebner R, Devoto MH, Weil D et al:Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 88:1380-1386, 2004
10)木村亜紀子:甲状腺眼症と眼瞼.神経眼科 26:126-132,2009
11)Scott AB:Injection treatment of endocrine orbital myopathy. Doc Ophthalmol 58:141-145, 1984
12)Ebner R:Botulinum toxin type A in upper lid retraction of Graves'ophthalmopathy. J Clin Neuroophthalmol 13:258-261, 1993
13)井出 醇・脇舛耕一・柴 智子・他:日本人の解剖研究用献体を用いた眼瞼のmagnetic resonance imagingとその組織像の対比所見.日眼会誌 113:1125-1131,2009
14)Bartley GB, Fatourechi V, Kadrmas EF et al:Clinical features of Graves'ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284-290, 1996
15)髙橋次郎:眼瞼腫脹の鑑別と治療5.全身疾患によるもの.眼科 49:795-803,2007
16)Le Moil R, Baldeschi L, Saeed P et al:Determination of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 17:357-362, 2007
17)Sambrook PN:Glucocorticoid osteoporosis. Curr Pharm Des 8:1877-1883, 2002
18)Tyrrell JB, Baxter JD:Disorders of the adrenal cortex. In:Wyngaarden JB, Smith LH Jr, Bennett JC(eds):Cecil Textbook of Medicine. 19th ed. 1271-1291, WB Saunders Philadelphia, 1992